目的:对药品集团采购供应链风险水平进行评价有助于发掘风险诱因,提升供应链风险应对能力。方法:基于SCOR模型并结合全面风险管理理论,对药品集团采购供应链风险因素进行识别与筛选,得出32项风险评价指标,并运用BP神经网络建立风险评价...目的:对药品集团采购供应链风险水平进行评价有助于发掘风险诱因,提升供应链风险应对能力。方法:基于SCOR模型并结合全面风险管理理论,对药品集团采购供应链风险因素进行识别与筛选,得出32项风险评价指标,并运用BP神经网络建立风险评价模型,收集风险数据开展评价。结果:当前我国药品集团采购供应链处于一般风险水平,采购与制造是风险最高的两个流程,各流程均存在较高风险水平指标。结论:需要重点解决问题有:提升药品集团采购供应链对宏观环境变化的应对能力、增强药品供应稳定性与及时性以及保证药品质量与生产过程合规;建议对策为:建立多元化供应结构、协同强化药品质量管理与合规监管、建立供应链风险信息共享机制与预警体系以及提高供应链弹性应对外部风险。Objective: Evaluating the risk level within pharmaceutical group procurement supply chains aids in identifying risk triggers and enhancing the capability to respond to supply chain risks. Methods: Based on the SCOR model and integrated with the theory of comprehensive risk management, this paper identifies and screens risk factors in pharmaceutical group procurement supply chains, deriving 32 risk evaluation indicators. A risk evaluation model is then established using BP neural networks, and risk data is collected for evaluation. Results: Currently, China’s pharmaceutical group procurement supply chains are at a moderate risk level, with procurement and manufacturing being the two processes with the highest risks. High-risk indicators are present in all processes. Conclusion: The primary risks that need addressing include improving the adaptability of pharmaceutical group procurement supply chains to macro-environmental changes, enhancing the stability and timeliness of drug supply, and ensuring drug quality and compliance in production processes. The recommended countermeasures are: establishing a diversified supply structure, collaboratively strengthening drug quality management and compliance oversight, establishing a supply chain risk information sharing mechanism and early warning system, and improving supply chain resilience to external risks.展开更多
文摘目的:对药品集团采购供应链风险水平进行评价有助于发掘风险诱因,提升供应链风险应对能力。方法:基于SCOR模型并结合全面风险管理理论,对药品集团采购供应链风险因素进行识别与筛选,得出32项风险评价指标,并运用BP神经网络建立风险评价模型,收集风险数据开展评价。结果:当前我国药品集团采购供应链处于一般风险水平,采购与制造是风险最高的两个流程,各流程均存在较高风险水平指标。结论:需要重点解决问题有:提升药品集团采购供应链对宏观环境变化的应对能力、增强药品供应稳定性与及时性以及保证药品质量与生产过程合规;建议对策为:建立多元化供应结构、协同强化药品质量管理与合规监管、建立供应链风险信息共享机制与预警体系以及提高供应链弹性应对外部风险。Objective: Evaluating the risk level within pharmaceutical group procurement supply chains aids in identifying risk triggers and enhancing the capability to respond to supply chain risks. Methods: Based on the SCOR model and integrated with the theory of comprehensive risk management, this paper identifies and screens risk factors in pharmaceutical group procurement supply chains, deriving 32 risk evaluation indicators. A risk evaluation model is then established using BP neural networks, and risk data is collected for evaluation. Results: Currently, China’s pharmaceutical group procurement supply chains are at a moderate risk level, with procurement and manufacturing being the two processes with the highest risks. High-risk indicators are present in all processes. Conclusion: The primary risks that need addressing include improving the adaptability of pharmaceutical group procurement supply chains to macro-environmental changes, enhancing the stability and timeliness of drug supply, and ensuring drug quality and compliance in production processes. The recommended countermeasures are: establishing a diversified supply structure, collaboratively strengthening drug quality management and compliance oversight, establishing a supply chain risk information sharing mechanism and early warning system, and improving supply chain resilience to external risks.
